FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Denies CAD/CADt Device 510(k) Exemption Petition

[ Price : $8.95]

FDA denies a petition seeking a partial exemption of 510(k) requirements for some specific radiology computer-aided detection and/...

Bipartisan Senators Urge FDA to Pre-Screen Certain Drug Ads

[ Price : $8.95]

Two bipartisan senators press FDA to take a more proactive role in policing prescription drug advertising, citing a surge in misle...

FDA Accepts Ultragenyx Resubmission for Gene Therapy

[ Price : $8.95]

Ultragenyx Pharmaceutical refiles a BLA seeking accelerated approval for UX111, an AAV9 gene therapy for the treatment of Sanfilip...

Makary Signals Push for Faster Approvals, and Sweeping Reforms

[ Price : $8.95]

In a wide-ranging 4/1 address to employees at FDA, commissioner Marty Makary outlines an expansive agenda to accelerate drug appro...

Kites Tecartus for Mantle Cell Lymphoma Gets Full Approval

[ Price : $8.95]

FDA grants full approval for Kites CAR-T cell therapy Tecartus (brexucabtagene autoleucel) for adult patients with relapsed or ref...

New CBER Head Should Restore Rare Disease Clarity: Advocates

[ Price : $8.95]

A rare disease coalition calls on the Trump administration to appoint a new CBER director who understands rare disease drug develo...

Multiple Violations at LeeSar Outsourcing Facility

[ Price : $8.95]

An FDA untitled letter cautions the Fort Myers, FL-based LeeSar drug outsourcing facility about CGMP and other violations in its p...

Multiple Violations in Physitemp Instruments Inspection

[ Price : $8.95]

FDA warns Clifton, NJ-based Physitemp Instruments about Quality System, Medical Device Reporting, Unapproved Device, and Unique De...

Appeals Court Hears GLP-1 Compounding Testimony

[ Price : $8.95]

A Courthouse New Service report outlines the competing arguments made before a three-judge appeals court panel in a case involving...

FDA Seeks Faster IND-To-Approval Timelines, Expanded OTC Access

[ Price : $8.95]

FDA commissioner Marty Makary says the agency is prioritizing efforts to accelerate drug development timelines beginning at the IN...